China News Service, Beijing, February 19 (Ren Jing) On the 19th, the State Council's joint prevention and control mechanism held a press conference.
At the meeting, Wu Liangyou, deputy director of the National Health Commission's Bureau of Disease Control and Prevention, said that recently, with the approval of the State Council's joint prevention and control mechanism, the National Health Commission has begun to deploy sequential booster immunizations.
Previously, all target groups over the age of 18 who have been vaccinated with Sinopharm Zhongsheng Beijing Company, Beijing Kexing Company, Sinopharm Zhongsheng Wuhan Company's inactivated vaccine or Tianjin CanSino Company's adenovirus vector vaccine for 6 months and over can receive one dose. Homologous booster immunization, that is, boosting with the original vaccine.
After the implementation of the sequential booster immunization strategy, the target population who has completed the whole process of inoculating the above three inactivated vaccines can also choose the recombinant protein vaccine of Zhifeilong Kema or the adenovirus vector vaccine of CanSino for sequential booster immunization.
For the target population, one of homologous booster immunization and sequential booster immunization can be selected.
Research data show that both homologous booster immunization and sequential booster immunization can further improve the immune effect.
Conference site.
Photo by Ren Jing